AstraZeneca data at ERS 2023 demonstrate leadership in transforming care across a broad respiratory portfolio of inhaled and biologic medicines
New data from Fasenra and Tezspire trials demonstrate AstraZeneca biologics progress towards achieving remission in severe asthma. New EXACOS-CV data uncover increased cardiopulmonary risk following COPD exacerbations.AstraZeneca will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from 9-13 September 2023. The company will present 93 abstracts, including 18 oral presentations, which will focus on unmet needs in severe asthma and